UniQure (QURE) Stock: Gene Therapy Company Drops 67% on FDA Data Concerns

TLDR UniQure stock fell 67% in premarket trading after the company disclosed the FDA’s changed position on AMT-130 The FDA no longer agrees Phase I/II study data with external controls is adequate for a Biologics License Application AMT-130 is an investigational gene therapy for Huntington’s disease that received Breakthrough Therapy designation in 2025 UniQure shares [...]

The post UniQure (QURE) Stock: Gene Therapy Company Drops 67% on FDA Data Concerns appeared first on Blockonomi.